ZNTL — Zentalis Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1725160 ·
Last close
$3.96
Market Cap
$281.90M
52W High
$6.95
52W Low
$2.07
ADV30
1,265,126
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -37,855,000 | -35,352,000 | 253,066,000 | 31,930,000 | 70,386,000 |
| Dec 2025 | 0 | — | -37,393,000 | -35,216,000 | 288,967,000 | 35,995,000 | 72,763,000 |
| Sep 2025 | 0 | — | -33,734,000 | -26,691,000 | 327,250,000 | 39,072,000 | 74,376,000 |
| Jun 2025 | 0 | — | -36,058,000 | -26,874,000 | 351,707,000 | 37,599,000 | 77,212,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-125,247,000
Investing CF
$131,623,000
Financing CF
$-4,282,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.97
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,191,455,000
Inventory
—
Receivables
$0
ST Investments
$209,898,000
EBIT TTM
$-145,012,000
Pretax Income TTM
$-136,618,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -145,012,000 | -137,060,000 | 288,967,000 | 72,763,000 | — | -125,247,000 |
| Dec 2024 | 67,425,000 | -187,458,000 | -165,839,000 | 430,337,000 | 93,151,000 | — | -170,860,000 |
| Dec 2023 | 0 | -253,941,000 | -292,191,000 | 551,688,000 | 114,297,000 | — | -207,822,000 |
| Dec 2022 | 0 | -227,287,000 | -236,806,000 | 539,310,000 | 105,286,000 | — | -163,751,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-154,278,000
OpCashFlow TTM
$0
Assets (Latest)
$430,337,000
Forward EPS
$-1.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGNX | MACROGENICS INC | $284.13M | $4.47 | — |
| AKBA | Akebia Therapeutics, Inc. | $278.99M | $1.04 | — |
| NVCT | Nuvectis Pharma, Inc. | $267.91M | $10.10 | — |
| ACIU | AC Immune SA | $298.20M | $2.93 | — |
| PRLD | Prelude Therapeutics Inc | $265.51M | $4.09 | — |
News headlines (Yahoo Finance, 1h cache)
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at
2026-05-21 21:39 · Yahoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-05-13 20:05 · Yahoo
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
2026-05-12 20:05 · Yahoo
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
2026-05-05 12:00 · Yahoo
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 21:30 · Yahoo
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
2026-04-21 14:27 · Yahoo
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target
2026-04-20 14:47 · Yahoo
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026
2026-04-17 19:15 · Yahoo
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone
2026-04-13 02:11 · Yahoo
Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
2026-04-09 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.